Answers are grounded in this paper and cite their sources.
Clinical Pharmacology & Therapeutics (2008); 83, 5, 651–654. doi:10.1038/clpt.2008.65 The envisioned future for medicine has as a central theme personalization of disease management.1 This transformative paradigm of customized, patient-specific strategies requires genetic, epigenetic, and/or system-level prioritization of disease risk and manifestation matched by selection of therapeutic intervention tailored for individual patients.2 Implementation of this paradigm in practice presumes that precision targeting of molecules, signaling networks, and macroprocesses central to the initiation, evolution, or maintenance of disease in an individual will avoid disease, reverse underlying pathophysiology, and repair damage while minimizing adverse off-target effects.3 This nascent concept, based on human genetic variation and individuality, is powerful in its simplicity; it is rendered emergent by the virtually unlimited analytic power of enabling technologies encompassing molecular profiling, systems biology, and in silico discovery and informatics.4 These scientific advances ultimately belie the complexity of the vision. There are approximately 25,000 genes estimated in humans, but the diversity of information encoded therein is exponentially compounded by an estimated more than 100,000 splice variants of messenger RNA transcripts. Indeed, there are an estimated 15 million loci along the genome where a single base can differ between individuals or populations. More than 3 million such locations, known as single-nucleotide polymorphisms, or SNPs, have been identified. This catalog, the HapMap, has been used through genome-wide association studies to map genes involved in complex diseases.5 The breathtaking scope of molecular diversity encoded in genetic polymorphisms—along with newly discovered levels of genetic regulation, including epigenetic modifications and microRNA, and approximately 106 protein states imposed by post-translational modifications with potential functional consequences—underscores the complexity of the goal of individualization through diagnostic and therapeutic targeting. However, although these considerations highlight the formidable challenges inherent in the biological diversity of the species at the individual level, they bring into specific relief the abundant opportunities for individualized medicine and targeted therapeutics.6 Advances in mapping complex disease processes, in conjunction with the development of high-throughput drug discovery and validation platforms, collectively offer unique opportunities in advancing individualized therapy from bench to bedside. This revolution in patient management is predicated on the development and refinement of therapeutic targets that move beyond classical models of disease palliation to disease avoidance and cure, in both individual patients and populations.7 The decoding of the human genome, coupled with logarithmic advances that permit ultra-rapid biomolecular analysis, has produced the next generation of technologies providing therapeutic targets with increased disease sensitivity and specificity for improved patient-specific management. Moreover, application of these technologies to elucidating mechanisms that underlie pathophysiology has defined biological components with dimensions that extend beyond generalized therapeutic interventions to mechanism-based targets for individualized therapy. A case in point is the emergence of technological platforms for implementation of therapeutic repair based on the increasingly understood principles of regenerative medicine applied through autologous or allogeneic approaches of stem cell–based therapy. Importantly, this ongoing technological revolution in discovery science has produced an unprecedented biotechnological transformation across the continuum of diagnostic and therapeutic development to realize the promise and potential of therapeutic targets in individualized and population medicine. Technological advances in target discovery have entrained the co-evolution of paradigms addressing target validation, therapeutic qualifications of efficacy, and application in practice. This concurrence in the development of validation paradigms for therapeutic targets has engendered newly recognized issues surrounding approval by regulatory agencies.7 In turn, advances in regulation, the emergence of requirements for robust target validation and therapeutic efficacy, and the attendant patient- and capital-intensive resources necessary to support these activities have driven the formation of new collaborative networks among federal agencies, academia, and the pharmaceutical/biotechnology industries to exploit the full potential of molecular targets in clinical care.8,9 The science of individualized therapy has been driven by the parallel development of high-throughput technologies and conceptual advances in molecular mechanisms underlying disease that have yielded targets of increasing complexity to address personalization of medical management.2,3 Initially, therapy evolved as agents influencing disease progression, such as penicillin with Gram-positive infections, insulin with diabetes, and salicylates with inflammation. More recently, developed therapeutic targets exploit technological and mechanistic advances, for example, small-molecule inhibitors with cancer, protease inhibitors with HIV disease, vaccine development with emerging infections, and lipid-lowering agents with atherosclerotic disease. Moreover, linear approaches involving isolated molecular targets have progressed, reflecting biosystem-wide insights into pathophysiology, and panels of targets and their disease-specific alterations have been quantified and their integrated therapeutic value defined. Beyond specific pathways, the entire transcriptome, proteome, metabolome, and kinome can be assessed, distinguishing molecules central to disease and amenable to intervention as "druggable" targets.6 The pace of therapeutic target discoveries—which has been prolific, reflecting the emergence of technologies—and their potential to change patient management mandate the concomitant refinement of development, regulation, and application strategies for realization of full clinical potential.10 In particular, regulatory oversight of target validation and qualification of clinical efficacy is imperative to facilitate systematic transition of target discovery to clinical care.11,12,13 Therapeutic targets emerging from broad-based, large-scale molecular profiling programs must advance through rigorous clinical validation to define metrics of safety and efficacy. In turn, these efforts will benefit exponentially from the development of molecular biomarkers of disease risk, prognosis, prediction, and prevention that are emerging in parallel and that have been rigorously cross-validated to ensure the highest levels of reproducibility.14 Additionally, quantitative and qualitative relationships among therapeutic targets, their associated biomarkers, and disease initiation and progression must undergo clinical qualification, with evidence linking therapeutic targets with biological and clinical endpoints.15 Moreover, relationships describing the clinical utility of therapeutic targets and their associated biomarkers will require careful evaluation in adequately powered prospective randomized clinical trials and subsequent validation in follow-up trials. The evolution of targeted therapeutics in clinical paradigms for patient management will further benefit from continual improvements across the pharmacotherapeutic continuum of discovery, development, regulation, and utilization, requiring collaboration across communities of practice.7 Target identification to optimize disease-free survival for patients will be based on comprehensive clinically annotated relational databases of patient cohorts followed longitudinally to compare individual molecular profiles with clinical characteristics of patients and pathologic characteristics of diseases.2 To maximize accessibility, applicability, and utility, databases and related biorepositories will be constructed utilizing common statistical algorithms, universally accepted trial designs, and standardized analytical platforms. Realization of personalized medicine algorithms in community practice to individualize patient therapies across whole populations will be based, in part, on an integrated grid of biomarkers to define disease prognosis, predict responsiveness to specific targeted therapies, and anticipate and avoid adverse reactions.7 This envisioned future mandates collaboration among stakeholders involved in target development, application, and regulation. Progress may be impeded by ethical issues surrounding patient confidentiality, privacy rights, and the fear of misuse of molecular data for discrimination.16 Importantly, there is recognition that barriers will be overcome and progress will be enjoyed through strategic alignment around a common vision. This vision is embodied in both the Critical Path Initiative promoted by the US Food and Drug Administration (FDA) and the Biomarkers Consortium, a collaboration among the Pharmaceutical Research and Manufacturers of America, the FDA, and the Foundation for the National Institutes of Health, in collaboration with the Centers for Medicare and Medicaid Services, academic institutions, and representatives from the private sector, including the pharmaceutical, biotechnology, and diagnostics industries.10,12,14 These cooperative strategic programs represent a requisite first step toward realizing the vision of individualized targeted therapy. Molecular targets for individualized therapy represent a path forward from the current palliative model of patient care to disease avoidance and cure. However, their integration into mainstream clinical practice is predicated on the evolution of development and regulatory paradigms centered on target validation, qualification of clinical efficacy, and the evidence basis of practice grounded in rigorous clinical trial design, analytical methodologies, and statistical evaluation. In conjunction, regulatory quality control and oversight will continue to evolve in this rapidly developing field.17 Moreover, progress will be achieved only in the context of collaboration between academic, private, and governmental sectors. These are the challenges that will confront the next generation of clinical pharmacologists as the field of individualized therapy evolves from single molecules to interacting pathways and beyond to entire biological systems.18 The challenges are matched only by the unprecedented opportunities for exponential advancement as this envisioned future is embraced. Indeed, therapeutic targeting emerges as a crucible, in which convergent forces interact to realize individualized medicine. The authors declared no conflict of interest. S.A.W. is the Samuel M.V. Hamilton Endowed Professor of Thomas Jefferson University. A.T. is the Marriott Family Professor of Cardiovascular Research of the Mayo Clinic.
No takes yet. Share an insight, caveat, or question.
Waldman et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: